DavidChienMD

Nuclear Medicine • Westlake Village, CA

Senior Vice President at Krystal Biotech

Join to view full profile

Dr. Chien is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chien's full profile

Already have an account?

Office
David Chien M.D.
Westlake Village, CA 91362

Summary

https://www.linkedin.com/in/davidchienmd/
https://www.krystalbio.com/about-us/leaders/

Education & Training

Johns Hopkins University School of MedicineFellowship, PET/CT, 2010 - 2011
Johns Hopkins UniversityResidency, Nuclear Medicine, 2007 - 2010
New York-Presbyterian/QueensInternship, Internal Medicine, 2006 - 2007
University of California, Davis, School of MedicineClass of 2006

Certifications & Licensure

CA State Medical License 2011 - 2025
NY State Medical License 2010 - 2012
PA State Medical License 2010 - 2012
American Board of Nuclear Medicine Nuclear Medicine
Certification Board of Nuclear CardiologyNuclear Cardiology

Awards, Honors, & Recognition

National Research Service Award NIH, 2010
Young Investigator Award Society of Nuclear Medicine, 2009
Morton Levitt Research Award University of California Davis, 2004

Clinical Trials

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2012 May 21
Completed
Phase 1
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199 Start of enrollment: 2013 Dec 01
Completed
Phase 1
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 Start of enrollment: 2014 Apr 01
Withdrawn
Phase 1
An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma Start of enrollment: 2013 Dec 20
Completed
Phase 1
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL) Start of enrollment: 2014 Dec 01
Completed
Phase 2
Study Evaluating Venetoclax in Subjects With Hematological Malignancies Start of enrollment: 2014 Sep 22
Completed
Phase 1, Phase 2
Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab Start of enrollment: 2016 May 25
Completed
Phase 3
Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab Start of enrollment: 2016 May 17
Completed
Phase 3
A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors Start of enrollment: 2015 Dec 01
Completed
Phase 1, Phase 2
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors Start of enrollment: 2016 Dec 19
Completed
Phase 1, Phase 2
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2017 Jun 09
Terminated
Phase 1, Phase 2
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer Start of enrollment: 2018 Apr 04
Completed
Phase 1, Phase 2
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma Start of enrollment: 2018 Sep 21
Completed
Phase 3
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) Start of enrollment: 2018 Dec 18
Terminated
Phase 3
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer Start of enrollment: 2019 Apr 29
Completed
Phase 2
A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH Start of enrollment: 2019 Jan 22
Completed
Phase 3
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Start of enrollment: 2020 Feb 05
Completed
Phase 3
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence Start of enrollment: 2020 Jul 27
Terminated
Phase 3
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread Start of enrollment: 2020 Sep 11
Completed
Phase 1
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer Start of enrollment: 2021 Jun 03
Terminated
Phase 1, Phase 2
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) Start of enrollment: 2022 Mar 09
Terminated
Phase 2, Phase 3
Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma Start of enrollment: 2021 Aug 05
Terminated
Phase 2
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies Start of enrollment: 2018 Mar 15
Terminated
Phase 1, Phase 2
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors Start of enrollment: 2019 Dec 30
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

9 citations
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen
European Urology. 2022-10-01
16 citations
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
Nizar M Tannir, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen
Journal for Immunotherapy of Cancer. 2022-04-01
6 citations
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Alexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, Dirk Schadendorf, Genevieve Boland
Future Oncology. 2022-03-01

Journal Articles

Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial
Zegers CM, van Elmpt W, Szardenings K, Kolb H, Waxman A, Subramaniam RM, Moon DH, Brunetti JC, Srinivas SM, Lambin P, Chien D, Eur J Nucl Med Mol Imaging, 1/1/2015
Optimum lean body formulation for correction of SUV in PET imaging
Tahari AK, Chien D, Azadi JR, Wahl RL, J Nucl Med, 1/1/2014
Early clinical PET imaging results with the novel PHF-Tau radioligand [F-18]-T808
Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su MY, Elizarov A, Kolb H, J Alzheimers Dis, 1/1/2013
Washout of Rb-82 as a marker of impaired tissue integrity obtained by list-mode cardiac PET/CT – Relationship with perfusion/metabolism patterns of myocardial viability
Chien DT, Higuchi T, Bravo P, Merrill J, Bengel FM, Eur J Nucl Med Mol Imaging, 1/1/2011
Imaging of the Parathyroid Glands
Chien D and Jacene H, Otolaryngol Clin North Am, 1/1/2010
Normal ranges for left ventricular ejection fraction and volumes from electrocardiographically gated Rb-82 cardiac PET/CT using four different commercially available s...
Bravo P, Chien D, Javadi MS, Merrill J, Bengel FM, J Nucl Med, 1/1/2010
I-124 PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison
Hobbs RF, Wahl RL, Lodge MA, Javadi MS, Cho SY, Chien DT, Ewertz ME, Esaias CE, Ladenson PW, Sgouros G, J Nucl Med, 1/1/2009
California ground squirrel (Spermophilus beecheyi) defenses against rattlesnake venom digestive and hemostatic toxins
Biardi JE, Chien D, Coss RG, Journal of Chemical Ecology, 1/1/2005
PCR isolation and cloning of novel splice variant mRNAs from known drug target genes
Jin P, Fu GK, Wilson AD, Yang J, Chien D, Hawkins PR, Au-Young J, Stuve LL, Genomics, 1/1/2004
Join now to see all

Abstracts/Posters

Phase 1 preliminary safety, efficacy, and biomarker data from venetoclax (ABT-199/GDC-0199) + bendamustine and rituximab in R/R non-Hodgkin’s lymphoma
de Vos S, Swinnen L, Kozloff M, Wang D, Reid E, Nastoupil L, Fowler N, Cordero J, Gifford M, D’Amico D, Dunbar M, Zhu M, Agarwal S, Ross J, Punnoose E, McKeegan E, Hei..., Hematol Oncol, 1/1/2015
A dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine and rituximab in patients with relapsed/refractory non-Hodgkin’s lymphoma
de Vos S, Flowers C, Wang D, Swinnen L, Fowler N, Reid E, Cordero J, Gifford M, D’Amico D, Dunbar M, Zhu M, Salem A, Heitner-Enschede S, Ricker JL, Chien D, Humerickho..., Haematologica, 1/1/2015
Hypoxia [18F] HX4 PET imaging in patients with head and neck cancer: repeatability and stability during radiotherapy
Zegers C, Van Elmpt W, Hoebers F, Chien D, Lambini P, Radiotherapy and Oncology, 1/1/2015
Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relaps...
de Vos S, Flowers C, Wang D, Swinnen L, Fowler N, Reid E, Cordero J, Gifford M, D’Amico D, Dunbar M, Zhu M, Salem A, Heitner-Enschede S, Ricker JL, Chien D, Humerickho..., J Clin Oncol, 1/1/2015
The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma
de Vos S, Flowers C, Wang D, Swinnen L, Fowler N, Reid E, Gifford M, D’Amico D, Dunbar M, Zhu M, Yang J, Heitner-Enschede S, Ricker JL, Chien D, Humerickhouse R, Kozlo..., Blood, 1/1/2014
First Case Report: Image to Autopsy Correlation for Tau Imaging with [18F]-T808 (AV-680)
Kolb HC, Attardo G, Mintun MA, Chien D, Elizarov A, Conti P, Miller CA, Joshi A, Skovronsky D, Alzheimers Dement, 1/1/2013
Exploratory analyses of regional human brain distribution of the PET tau tracer F18-labeled T807 (AV-1541) in subjects with normal cognitive function or cognitive impa...
Mintun MA, Schwarz A, Joshi A, Shcherbinin S, Chien D, Elizarov A, Su MY, Shankle W, Pontecorvo MJ, Tauscher J, Skovronsky D, Kolb HC, Alzheimers Dement, 1/1/2013
Low-dose propranolol is safe for use in pediatric patients to decrease FDG brown adipose tissue uptake
Green A, Chien D, Luber B, Wang H, Wahl RL, Cho S, J Nucl Med, 1/1/2013
Low-dose propranolol (LDP) is effective in suppressing FDG brown adipose tissue (BAT) uptake in pediatric patients: Qualitative and quantitative analyses
Chien D, Chaudhry M, Wahl RL, Cho S, J Nucl Med, 1/1/2011
Feasibility and potential limitations of PERCIST 1.0 criteria for comparison of sequential studies in routine clinical practice
Chien D and Wahl RL, J Nucl Med, 1/1/2011
Effects of serum glucose on SUL of normal liver, a dynamic glucose metabolism organ
Chien D and Wahl RL, J Nucl Med, 1/1/2011
Relationship of age, gender and body morphometry to normal hepatic SUL: Paradoxically low hepatic SUL in morbidly obese women
Chien D and Wahl RL, J Nucl Med, 1/1/2011
Reproducibility of liver and mediastinal blood pool F-18 activity as normal reference tissues
Chien D, Lodge M, Wahl RL, J Nucl Med, 1/1/2011
Normal hepatic SUL measured over a wide range of time points post FDG injection - Potential application in background correction in quantitative PET
Chien D, Chaudhry M, Wahl RL, J Nucl Med, 1/1/2011
Reproducibility of “glucose corrected” hepatic SUL compared to uncorrected hepatic SUL in baseline and follow-up studies
Chien D and Wahl RL, J Nucl Med, 1/1/2011
Impaired global myocardial blood flow and flow reserve in patients with chronic renal insufficiency and normal LV function and regional perfusion on clinical Rb-82 car...
Fukushima K, Javadi M, Higuchi T, Merrill J, Bravo P, Lautamaki R, Chien D, and Frank BM, J Nucl Med, 1/1/2010
Systematic evaluation of pediatric FDG uptake by brown adipose tissue
Chien D and Cho S, Am J Roentgenol, 1/1/2010
Evaluation of degree and extent of FDG BAT uptake in pediatric patients utilizing semi-quantitative and quantitative analysis
Chien D and Cho S, J Nucl Med, 1/1/2010
124-I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning
Hobbs RF, Lodge MA, Wahl RL, Javadi S, Cho SY, Chien D, Ewertz ME, Ladenson PW, and Sgouros G, J Nucl Med, 1/1/2009
Normal ranges for left ventricular ejection fraction and volumes from electrocardiographically gated 82Rb cardiac PET/CT using four different softwares
Bravo P, Chien D, Javadi MS, Merrill J, and Bengel FM, J Nucl Med, 1/1/2009
Washout of rubidium-82 as a marker of impaired membrane integrity, obtained by list-mode cardiac PET/CT – Relationship with perfusion / metabolism patterns of myocardi...
Chien D, Takahiro H, Paco B, Jennifer M, and Frank BM, Cardiovascular Council Young Investigator Award Symposium; J Nucl Med, 1/1/2009
Reproducibility of software measurements of left ventricular ejection fraction and volume measurements from electrocardiographically gated 82Rb cardiac PET/CT
Bravo P, Chien D, Javadi M, Merril J, Bengel F, J Nucl Med, 1/1/2009
Glycopyrrolate is safe in the middle ear of gerbils – Implication in treatment of post-mastoidectomy complications
Chien D, Bordie HA, and Tinling S, National Student Research Forum, Galveston, TX, 1/1/2005
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

External Links

LinkedInhttps://www.linkedin.com/in/davidchienmd/